Pharmaceutical savings after gastric bypass surgery

Area of Science:

• Bariatric surgery
• Metabolic disease management
• Health economics

Background:

• Clinically severe obesity (CSO) is a significant health concern often managed surgically.
• Roux-en-Y gastric bypass (RYGBP) is a common bariatric procedure for CSO.
• RYGBP improves co-morbidities and is hypothesized to reduce medication needs.

Purpose of the Study:

• To evaluate the impact of RYGBP on medication expenditure in patients with severe obesity.
• To determine if weight loss post-RYGBP leads to significant cost savings.
• To assess the long-term financial benefits for patients and healthcare systems.

Main Methods:

• Retrospective analysis of the first 100 RYGBP patients at a community-teaching hospital.
• Inclusion criteria applied to 64 patients with adequate follow-up data.
• Wilcoxon signed rank test used for statistical analysis of medication costs.

Main Results:

• Mean BMI of included patients was 57 kg/m², with a 4:1 female to male ratio and mean age of 44.
• Average monthly medication expenditure decreased from $317 preoperatively to $135 postoperatively.
• This reduction in medication costs was statistically significant (P < 0.01).

Conclusions:

• Weight loss following RYGBP results in substantial and significant reductions in medication expenses.
• These savings contribute to offsetting the initial cost of the bariatric surgery.
• The financial benefits represent a permanent saving for patients and society.